Clinical Trial

Monthly Dosing of Atacicept in IgAN

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-05; most recent amendment 2026-04-08.
Status change: Recruiting → Active, Not Recruiting 2026-04-08
Trial Details
NCT Number NCT07020923
Lead Sponsor Vera Therapeutics, Inc.
Conditions IgA Nephropathy (IgAN), Berger Disease
Enrollment 90 participants
Start Date 2025-05-29
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-13